Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403534 | 0.91 | CYP1A2 (0.54) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2410919 | 0.89 | CYP1A2 (0.52) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2406414 | 0.88 | CYP1A2 (0.51) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13830898 | 0.85 | MAPT (0.64) | LMNASMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL12269643 | 0.83 | L3MBTL1 (0.52) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2404613 | 0.83 | MAPT (0.60) | POLBMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL2407535 | 0.81 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2407561 | 0.81 | CYP1A2 (0.44) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2405599 | 0.80 | LMNA (0.50) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2405407 | 0.79 | MAPT (0.56) | LMNAPOLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | CHKA, CHKB, CEPT1 | LMNA 2890/4885SMN1; SMN2 3409/4885CYP1A2 3750/4885 |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | LMNA 1499/4885SMN1; SMN2 700/4885CYP1A2 3925/4885 |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | LMNA 1657/4885SMN1; SMN2 889/4885CYP1A2 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.